Login / Signup

Clinical and Pathological Predictors of Death for Adrenocortical Carcinoma.

Eduardo PatoVictor SrougiClaudia ZerbiniFelipe L LedesmaFabio TannoMadson Q AlmeidaWilliam NahasAna Claudia LatronicoBerenice B MendoncaJose L ChambôMaria Candida Barisson Villares Fragoso
Published in: Journal of the Endocrine Society (2024)
Adrenocortical carcinoma (ACC) is a rare and lethal disease with a poor prognosis. This study aims to share our 41-year experience as a referral center, focusing on identifying risk factors associated with ACC mortality. Our retrospective analysis included a cohort of 150 adult patients with ACC in all stage categories, treated between 1981 and 2022. Tumor hormonal hypersecretion was observed in 78.6% of the patients, and the median age of diagnosis was 40 years. The majority presented as European Network for the Study of Adrenal Tumors (ENSAT) III or IV (22.9% and 31.2%, respectively), and the overall mortality rate was 54.6%. Independent predictors of death were elevated secretion of cortisol (HR = 2.0), androstenedione (HR = 2.2), estradiol (HR = 2.8), 17-OH progesterone (HR = 2.0), and 11-deoxycortisol (HR = 5.1), higher Weiss (HR = 4.3), modified Weiss (HR = 4.4), and Helsinki scores (HR = 12.0), advanced ENSAT stage (HR = 27.1), larger tumor size (HR = 2.7), higher Ki-67 percentage (HR = 2.3), and incomplete surgical resection (HR = 2.5). Mitosis greater than 5/50 high-power field (HR = 5.6), atypical mitosis (HR = 2.3), confluent necrosis (HR = 15.4), venous invasion (HR = 2.8), and capsular invasion (HR = 2.4) were also identified as independent predictors of death. Knowing the risk factors for ACC's mortality may help determine the best treatment option.
Keyphrases
  • poor prognosis
  • long non coding rna
  • metabolic syndrome
  • cardiovascular events
  • chronic kidney disease
  • risk factors
  • ejection fraction
  • cardiovascular disease
  • end stage renal disease
  • skeletal muscle